title: Clinical translation in multiple myeloma: from bench to bedside.
abstract: The outlook for patients with multiple myeloma (MM) has improved significantly with the development of new and more effective therapies, particularly the immunomodulatory agents and proteasome inhibitors. Preclinical and correlative science investigations have played a critical role in these advances, providing important insights regarding mechanisms of neoplasia, inhibition of tumor growth, and drug resistance. This review highlights the evolution of drug development in MM, the manner in which preclinical models have contributed to the process of drug discovery, and important insights gained during the current era of MM drug development.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA. Electronic address: jacob_laubach@dfci.harvard.edu.
authors.forename: Jacob
authors.initials: J
authors.lastname: Laubach
authors.forename: Teru
authors.initials: T
authors.lastname: Hideshima
authors.forename: Paul
authors.initials: P
authors.lastname: Richardson
authors.forename: Kenneth
authors.initials: K
authors.lastname: Anderson
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D015195:Drug Design; D006801:Humans; D051379:Mice; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000503:physiopathology; D046988:Proteasome Endopeptidase Complex; D061988:Proteasome Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex